ZIVO Bioscience, Inc. (ZIVO)
- Previous Close
0.00 - Open
19.00 - Bid 18.00 x 40000
- Ask 19.00 x 29200
- Day's Range
19.00 - 19.00 - 52 Week Range
3.13 - 22.15 - Volume
100 - Avg. Volume
583 - Market Cap (intraday)
67.666M - Beta (5Y Monthly) -0.07
- PE Ratio (TTM)
-- - EPS (TTM)
-4.23 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.
www.zivobioscience.comRecent News: ZIVO
View MorePerformance Overview: ZIVO
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZIVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZIVO
View MoreValuation Measures
Market Cap
67.67M
Enterprise Value
66.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
362.60
Price/Book (mrq)
--
Enterprise Value/Revenue
422.20
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-759.60%
Return on Equity (ttm)
--
Revenue (ttm)
157.22k
Net Income Avi to Common (ttm)
-13.38M
Diluted EPS (ttm)
-4.23
Balance Sheet and Cash Flow
Total Cash (mrq)
1.54M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
752.71k